For the year ending 2025-12-31, GMED made $2,938,931K in revenue. $560,075K in net income. Net profit margin of 19.06%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Net sales | 2,938,931 | 2,519,355 | ||
| Cost of sales (exclusive of amortization of intangibles) | 957,802 | 1,035,479 | ||
| Research and development | 147,246 | 163,754 | ||
| Selling, general and administrative | 1,178,498 | 981,048 | ||
| Provision for litigation, net | - | 314 | ||
| Amortization of intangibles | 118,194 | 119,373 | ||
| Acquisition-related costs | 42,326 | 29,623 | ||
| Restructuring costs | 15,049 | 23,773 | ||
| Operating income/(loss) | 479,816 | 165,991 | ||
| Interest income/(expense), net | 7,141 | - | ||
| Foreign currency transaction gain/(loss) | -3,006 | -43,285 | ||
| Bargain purchase gain | 117,704 | - | ||
| Interest income/(expense), net | - | -4,189 | ||
| Other income/(expense) | 3,413 | 2,205 | ||
| Total other income/(expense), net | 125,252 | -45,269 | ||
| Income/(loss) before income taxes | 605,068 | 120,722 | ||
| Income tax provision/(benefit) | 67,200 | 17,738 | ||
| Net income/(loss) | 537,868 | 102,984 | ||
| Unrealized gain/(loss) on marketable securities | 448 | 1,545 | ||
| Foreign currency translation gain/(loss) | 21,759 | 1,786 | ||
| Total other comprehensive income/(loss), net of tax | 22,207 | 3,331 | ||
| Comprehensive income/(loss) | 560,075 | 106,315 | ||
| Basic EPS | 3.98 | 0.76 | ||
| Diluted EPS | 3.92 | 0.75 | ||
| Basic Average Shares | 135,215,000 | 135,726,000 | ||
| Diluted Average Shares | 137,056,000 | 137,863,000 | ||
GLOBUS MEDICAL INC (GMED)
GLOBUS MEDICAL INC (GMED)